Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative effectiveness and safety between reduced dose dabigatran, reduced dose rivaroxaban and warfarin in elderly Atrial Fibrillation Patients over 85 years

Next Previous
Trial Profile

Comparative effectiveness and safety between reduced dose dabigatran, reduced dose rivaroxaban and warfarin in elderly Atrial Fibrillation Patients over 85 years

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Embolism and thrombosis; Ischaemic stroke; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 Jul 2018 Results (n=4722) published in the Journal of the American Geriatrics Society.
  • 28 Nov 2017 New trial record
  • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top